Core Viewpoint - Thermo Fisher Scientific is expected to report a year-over-year decline in earnings and revenues, with the stock's movement heavily dependent on how actual results compare to consensus estimates [3][6][11]. Revenue and Earnings Expectations - Revenues for the upcoming quarter are projected to be $10.51 billion, reflecting a decrease of 1.7% compared to the same quarter last year [2]. - The expected earnings per share (EPS) for Thermo Fisher is $5.13, indicating a year-over-year change of -0.4% [13]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model indicates a negative Earnings ESP of -0.43%, suggesting analysts have become bearish on the company's earnings prospects [6][15]. - The consensus EPS estimate has been revised 0.14% lower over the last 30 days, indicating a reassessment by covering analysts [14]. Historical Performance - Over the last four quarters, Thermo Fisher has beaten consensus EPS estimates three times, which may influence expectations for the upcoming report [9][18]. - For the last reported quarter, the company was expected to post earnings of $4.70 per share but delivered $5.11, resulting in a surprise of +8.72% [18]. Analyst Sentiment - The current Zacks Rank for Thermo Fisher is 2 (Buy), which may provide some support for the stock despite the negative Earnings ESP [17].

Thermo Fisher Scientific Inc. (TMO) is slated to release second-quarter 2024 results on Jul 24, before market open. Thermo Fisher's first-quarter earnings of $5.11 per share beat the Zacks Consensus Estimate by 8.7%. Its earnings missed estimates in one of the trailing four quarters and beat in the other three, the average surprise being 1.52%. Q2 Estimates The Zacks Consensus Estimate for second-quarter revenues is pegged at $10.51 billion, suggesting a 1.6% decline from the prior-year quarter's reported f ...

Loading... Loading... Stocks tend to sell off after they reach resistance. They also tend to rally off of support. These dynamics can be seen on the chart of Thermo Fisher Scientific Inc. TMO. This is why our trading team has selected it as our Stock of the Day. Thermo Fisher Scientific · 1D · NYSE · 0 0 · 0546.59 H549.61 L543.85 C548.73 +0.63 (+0.12%) 610.00 600.00 590.00 560.00 2024 Feb Mar May Jun Jul Aug Resistance is a large group or concentration of sellers who are looking to sell at, or close to, the ...

Thermo Fisher Scientific Inc. (TMO) recently announced a partnership with the National Cancer Institute ("NCI") for the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. Under the trial, patients' bone marrow and blood will be tested for certain genetic biomarkers using Thermo Fisher's next-generation sequencing ("NGS") technology. With this, clinical sites can quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mut ...

Investors with an interest in Medical - Instruments stocks have likely encountered both Thermo Fisher Scientific (TMO) and Idexx Laboratories (IDXX) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels. TMO currently has a forward P/E ratio of 24.80, while IDXX has a forward P/E of ...

A few of its recent strategic acquisitions that are likely to drive future growth include its plan to acquire Olink Holdings for $26.00 per common share in cash, which was announced in October. The acquisition is expected to enhance Thermo Fisher's capabilities in the high-growth proteomics market with the addition of highly differentiated solutions. Through the acquisition, the company expects to deliver $125 million in adjusted operating income synergies in the fifth year, driven by revenue synergies and ...

The new 65,000-square-foot space in Covington, KY, will expand the company's sample management and biorepository operations. The latest development will be in addition to its existing site in nearby Highland Heights. More on the News Thermo Fisher Scientific Inc. (TMO) recently announced the expansion of its central laboratory operations in Kentucky under its PPD clinical research business. The latest addition will help TMO to accelerate pharmaceutical and biotech customers' delivery of safe, effective medi ...

Thermo Fisher Scientific (TMO) recently unveiled the PlasmidPro Maxi Processor (PlasmidPro), its latest addition to the Thermo Scientific KingFisher instrument portfolio. The solution has a comprehensive range of key features that sets it apart as the only fully automated maxi-scale plasmid DNA (pDNA) purification system. Image Source: Zacks Investment Research Thermo Fisher is addressing the rapidly growing demand for plasmid DNA purification for emerging therapies with a new 'press and go' solution to spe ...

Thermo Fisher Scientific Inc. (TMO) has announced a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, WI, under its PPD clinical research business. The addition of a 72,500-square-foot building is likely to improve the company's clinical development and laboratory services by expanding the site's chemistry, manufacturing and control (CMC) analytical capabilities. This, in turn, should help its customers provide high quality and safety standards for patient ...

Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produce vaccines and therapies globally. Thermo Fisher's business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augmen ...